Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide

被引:69
|
作者
Ciardiello, F
Caputo, R
Bianco, R
Damiano, V
Pomatico, G
Pepe, S
Bianco, AR
Agrawal, S
Mendelsohn, J
Tortora, G
机构
[1] Univ Naples Federico II, Fac Med & Chirurg, Cattedra Oncol Med, Dipartimento Endocrinol & Oncol Mol & Clin, I-80131 Naples, Italy
[2] Hybridon Inc, Cambridge, MA USA
[3] Univ Texas, Md Anderson Canc Ctr, Houston, TX USA
来源
关键词
D O I
10.1093/jnci/90.14.1087
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The expression of epidermal growth factor receptor (EGFR) and type I cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKAI) is associated with neoplastic transformation. By use of human renal cancer cell lines (i,e,, 769-P, ACHN, A498, and SW839), we investigated the antiproliferative activity and the antitumor activity of an anti-EGFR humanized chimeric mouse monoclonal antibody, MAb C225, and a novel mixed backbone 18-mer antisense oligonucleotide, HYB 190, that targets expression of the RI alpha regulatory subunit of PKAI, Methods: The antiproliferative activity of MAb C225 and oligonucleotide HYB 190, alone or in combination, on different renal cancer cell lines was determined by monitoring cell growth in soft agar, In addition, the induction of apoptosis by treatment with the anti-EGFR antibody and/or antisense PKAI oligonucleotides was evaluated by flow cytometric analysis of fragmented DNA, The antitumor activity of MAb C225 and oligonucleotide HYB 190 was determined in athymic mice bearing established ACHN tumor xenografts, Cell proliferation and tumor growth data were evaluated for statistical significance using Student's t test; reported P values are two-sided. Results: MAb C225 and oligonucleotide HYB 190 inhibited colony formation in soft agar in a dose-dependent manner for all renal cancer cell lines tested, We observed a potentiation of growth inhibition and induction of apoptosis when 769-P cells and ACHN cells were treated with both agents. Combination treatment with MAb C225 and oligonucleotide HYB 190 caused regression of ACHN tumor xenografts, whereas single-agent treatment only delayed tumor growth. Conclusion: The combination of anti-EGFR MAb C225 and HYB 190 antisense PKAI oligonucleotides HYB 190 exhibited cooperative antiproliferative effects and cooperative antitumor effects on EGFR and PKAI-expressing human renal cancer cell Lines.
引用
收藏
页码:1087 / 1094
页数:8
相关论文
共 50 条
  • [1] Inhibition of renal cancer growth by C225 anti-epidermal growth factor receptor monoclonal antibody and protein kinase A mixed backbone antisense oligonucleotide
    Ciardiello, F
    Caputo, R
    Bianco, R
    Pomatico, G
    Bianco, AR
    Agrawal, S
    Mendelsohn, J
    Tortora, G
    ANNALS OF ONCOLOGY, 1998, 9 : 81 - 81
  • [2] Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth
    Tortora, G
    Caputo, R
    Pomatico, G
    Pepe, S
    Bianco, AR
    Agrawal, S
    Mendelsohn, J
    Ciardiello, F
    CLINICAL CANCER RESEARCH, 1999, 5 (04) : 875 - 881
  • [3] Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer
    Nanjo, Shigeki
    Yamada, Tadaaki
    Takeuchi, Shinji
    Yano, Seiji
    CANCER RESEARCH, 2012, 72
  • [4] Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer
    Yamada, Tadaaki
    Takeuchi, Shinji
    Kita, Kenji
    Bando, Hideaki
    Nakamura, Takahiro
    Matsumoto, Kunio
    Yano, Seiji
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) : 272 - 280
  • [5] Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer
    Solbach, C
    Roller, M
    Ahr, A
    Loibl, S
    Nicoletti, M
    Stegmueller, M
    Kreysch, HG
    Knecht, R
    Kaufmann, M
    INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (04) : 390 - 394
  • [6] Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer
    Teramoto, T
    Onda, M
    Tokunaga, A
    Asano, G
    CANCER, 1996, 77 (08) : 1639 - 1645
  • [7] Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer
    Kajitani, Tatsuhiro
    Makiyama, Akitaka
    Arita, Shuji
    Shimokawa, Hozumi
    Oda, Hisanobu
    Shirakawa, Tsuyoshi
    Baba, Eishi
    Esaki, Taito
    ANTICANCER RESEARCH, 2017, 37 (11) : 6459 - 6468
  • [8] Role of an anti-epidermal growth factor receptor in treating cancer
    Waksal, HW
    CANCER AND METASTASIS REVIEWS, 1999, 18 (04) : 427 - 436
  • [9] Role of an Anti-epidermal Growth Factor Receptor in Treating Cancer
    Harlan W. Waksal
    Cancer and Metastasis Reviews, 1999, 18 : 427 - 436
  • [10] Anti-epidermal growth factor receptor drugs in cancer therapy
    Ciardiello, F
    Tortora, G
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) : 755 - 768